30 November 2017

In patients who receive a modern stent after a heart attack, a three-month treatment with dual antiplatelet therapy does not lead to more complications than with the current standard treatment of twelve months.

This is shown by international research presented by Harry Suryapranata during the cardiology TCT conference in Denver, USA.
The optimal treatment duration with blood thinners after implantation of a stent in patients with acute coronary syndrome is under discussion. We are constantly looking for an optimum between the risk of clotting and bleeding. Longer treatment with the usual two dual antiplatelet therapy reduces the risk of clotting problems (new heart attack, coagulation in the stent), but at the same time increases the risk of bleeding. The current recommendation - using twelve months of dual dual antiplatelet therapy after a stent implant - is based primarily on research with older stents.
Complications equal in both groups
The REDUCE study, which was conducted in 36 hospitals in Europe and Asia, uses a new bioactive stent, which promotes the natural recovery of the vascular wall. The study, which involved nearly 1500 patients, examined the difference between twelve or three months of use of dual antiplatelet therapy in this specific stent.
"The results show that after implantation of this stent, treatment duration of three months is not worse than the usual twelve months," says Harry Suryapranata, principal investigator of the study and professor of cardiology at Radboudumc. "In about 1 in 12 patients, we experienced one of the following complications in the first year after stent implant: deaths, myocardial infarctions, stent thromboses, strokes, new procedures in the treated coronary artery or bleeding complications. Based on these criteria, we saw no difference in complications between the group that was treated for twelve or three months.'
Important contribution
In the Radboudumc the REDUCE study was conducted under the supervision of intervention cardiologist Cyril Camaro and researcher Sander Damen. Camaro: "This research shows that a shorter treatment duration with dual anti-platelet therapy can be considered when needed, even in patients who have had a heart attack." Suryapranata, who presented the results at a conference in Denver: "It is an important and remarkable finding, but larger studies must confirm this hypothesis. Also because we now have many different types of anti-platelet agents. '

Suryapranata H, De Luca G. REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES with a Luminal CD34+Antibody Coating in Patients with ACS. Late Breaking Clinical Trial at the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium, November 1, 2017.
TCT congress: https://www.tctmd.com/news/shortened-dapt-durations-appear-safe-patients-acs-implanted-des

Related news items

More expertise needed for patients with prolonged Disorder of Consciousness

14 November 2019

Willemijn van Erp published in the Annals of Neurology that nearly 80% of people with Unresponsive Wakefulness Syndrome, formerly referred to as ‘vegetative state’, are not given a correct description of the diagnosis when they are discharged from the hospital.

read more

Martinus van Marum prize call for proposals

14 November 2019

The Martinus van Marum prize is given to young researchers (<5 years after PhD) for the original research they have conducted in science and technology.

read more

1.5 million for research into young people with mild intellectual disabilities

13 November 2019

Researchers from the Radboud University and Radboudumc will partner with social organisations to map how often young people with mild intellectual disabilities have psychological problems and how they can be treated. The project was recently awarded a subsidy of 1.5 million euro by ZonMw.

read more

Bart van de Warrenburg appointed visiting professor at the UKM Medical Centre in Kuala Lumpur

11 November 2019

Neurologist and Principal Investigator at the Donders Institute Bart van de Warrenburg has been appointed visiting professor at the UKM Medical Centre in Kuala Lumpur.

read more

KNAW Van Leersum beurs for Mohammad Alsady

7 November 2019

Mohammad Alsady, theme Disorders of movement, received the “KNAW Van Leersum beurs”.

read more

3D breast ultrasound elastography to improve breast cancer detection

5 November 2019

One out of seven women will be diagnosed with breast cancer during their life. Early detection of breast cancer is important to increase the survival rate. Gijs Hendriks graduated recently on a new technique, 3D elastography, to detect breast cancer better.

read more